618 related articles for article (PubMed ID: 8329837)
1. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human natural killer cell activity by platelet-derived growth factor. II. Membrane binding studies, effects of recombinant IFN-alpha and IL-2, and lack of effect on T cell and antibody-dependent cellular cytotoxicity.
Gersuk GM; Chang WC; Pattengale PK
J Immunol; 1988 Dec; 141(11):4031-8. PubMed ID: 2846698
[TBL] [Abstract][Full Text] [Related]
3. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
Chang WC; Hsiao MH; Pattengale PK
Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human natural killer cell activity by platelet-derived growth factor.
Gersuk GM; Holloway JM; Chang WC; Pattengale PK
Nat Immun Cell Growth Regul; 1986; 5(6):283-93. PubMed ID: 3796638
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. I. Defective trigger on NK cells for NKCF production by target cells, and partial restoration by IL 2.
Bonavida B; Katz J; Gottlieb M
J Immunol; 1986 Aug; 137(4):1157-63. PubMed ID: 3488345
[TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia.
Wang JC; Chang TH; Goldberg A; Novetsky AD; Lichter S; Lipton J
Exp Hematol; 2006 Dec; 34(12):1617-23. PubMed ID: 17157157
[TBL] [Abstract][Full Text] [Related]
7. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
Riley CH; Hansen M; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM; Jensen MK
Eur J Haematol; 2015 Mar; 94(3):227-34. PubMed ID: 25082025
[TBL] [Abstract][Full Text] [Related]
8. Progenitor cell trafficking in physiologic conditions and in myeloproliferative diseases: quantification of CD34+ cells by polymerase chain reaction.
Oppliger Leibundgut E; Brunold C; Marti D; Horn MP; Seiler C; Schroeder V; Schmid JP; Tobler A; Zwicky C
Haematologica; 2005 Jul; 90(7):875-80. PubMed ID: 15996924
[TBL] [Abstract][Full Text] [Related]
9. Generation of a lipid-like cytotoxin from human CD16+ natural killer cells.
Cosentino LM; Cathcart MK
Cancer Res; 1989 Dec; 49(23):6662-9. PubMed ID: 2531033
[TBL] [Abstract][Full Text] [Related]
10. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
11. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
12. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
13. [Megakaryoblastic transformation in polycythemia vera--a case of megakaryoblastic leukemia associated with myelofibrosis and elevation of serum PDGF-like activity].
Oda K; Katoh O; Kawano M; Iwato K; Kimura A; Imamura N; Fujimura K; Kuramoto A; Yasui W; Kajihara H
Rinsho Ketsueki; 1986 Nov; 27(11):2118-23. PubMed ID: 3820629
[No Abstract] [Full Text] [Related]
14. Antigenic phenotype of myelomonocytic progenitors (CFU-GM) in chronic myeloproliferative disorders.
Ferrero D; Tarella C; Pregno P; Pileri A; Gallo E
Cancer Res; 1986 Feb; 46(2):975-80. PubMed ID: 3455679
[TBL] [Abstract][Full Text] [Related]
15. Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells.
Gaddy J; Broxmeyer HE
Cell Immunol; 1997 Sep; 180(2):132-42. PubMed ID: 9341743
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders.
Passamonti F; Vanelli L; Malabarba L; Rumi E; Pungolino E; Malcovati L; Pascutto C; Morra E; Lazzarino M; Cazzola M
Haematologica; 2003 Oct; 88(10):1123-9. PubMed ID: 14555308
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of norepinephrine-mediated inhibition of human NK cytotoxic functions: inhibition of cytokine secretion, target binding, and programming for cytotoxicity.
Gan X; Zhang L; Solomon GF; Bonavida B
Brain Behav Immun; 2002 Jun; 16(3):227-46. PubMed ID: 12009684
[TBL] [Abstract][Full Text] [Related]
18. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus.
Park YW; Kee SJ; Cho YN; Lee EH; Lee HY; Kim EM; Shin MH; Park JJ; Kim TJ; Lee SS; Yoo DH; Kang HS
Arthritis Rheum; 2009 Jun; 60(6):1753-63. PubMed ID: 19479851
[TBL] [Abstract][Full Text] [Related]
19. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of human natural killer cell activity by platelet-derived growth factor (PDGF). III. Membrane binding studies and differential biological effect of recombinant PDGF isoforms.
Gersuk GM; Westermark B; Mohabeer AJ; Challita PM; Pattamakom S; Pattengale PK
Scand J Immunol; 1991 May; 33(5):521-32. PubMed ID: 1851574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
